Literature DB >> 33730109

High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome.

Ivan Sergeevich Moiseev1, Nikolay Yurevich Tcvetkov1, Ildar Munerovich Barkhatov1, Maria Vladimirovna Barabanshikova1, Dmitrii Sergeevich Bug2, Natalya Vitalievna Petuhova2, Artem Valerievich Tishkov2, Evgenyi Alexandrovich Bakin1, Ekaterina Andreevna Izmailova1, Alena Igorevna Shakirova1, Alexandr Dmitrievich Kulagin1, Elena Vladislavovna Morozova1.   

Abstract

A number of sequencing studies identified the prognostic impact of somatic mutations in myelodysplastic syndrome (MDS). However the majority of them focused on methylation regulation, apoptosis and proliferation genes. Despite the number of experimental studies published on the role of micro-RNA processing and checkpoint genes in the development of MDS, the clinical data about mutational landscape in these genes is limited. We performed a pilot study which evaluated mutational burden in these genes and their association with common MDS mutations. High prevalence of mutations was observed in the genes studied: 54% had mutations in DICER1, 46% had mutations in LAG3, 20% in CTLA4, 23% in B7-H3, 17% in DROSHA, 14% in PD-1 and 3% in PD-1L. Cluster analysis that included these mutations along with mutations in ASXL1, DNMT3A, EZH2, IDH1, RUNX1, SF3B1, SRSF2, TET2 and TP53 effectively predicted overall survival in the study group (HR 4.2, 95%CI 1.3-13.6, p = 0.016). The study results create the rational for incorporating micro-RNA processing and checkpoint genes in the sequencing panels for MDS and evaluate their role in the multicenter studies.

Entities:  

Year:  2021        PMID: 33730109      PMCID: PMC7968630          DOI: 10.1371/journal.pone.0248430

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  51 in total

1.  Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.

Authors:  Michael Heuser; Razif Gabdoulline; Patrick Löffeld; Vera Dobbernack; Henriette Kreimeyer; Mira Pankratz; Madita Flintrop; Alessandro Liebich; Sabrina Klesse; Victoria Panagiota; Michael Stadler; Martin Wichmann; Rabia Shahswar; Uwe Platzbecker; Christian Thiede; Thomas Schroeder; Guido Kobbe; Robert Geffers; Brigitte Schlegelberger; Gudrun Göhring; Hans-Heinrich Kreipe; Ulrich Germing; Arnold Ganser; Nicolaus Kröger; Christian Koenecke; Felicitas Thol
Journal:  Ann Hematol       Date:  2017-06-13       Impact factor: 3.673

2.  MicroRNA-223-3p modulates dendritic cell function and ameliorates experimental autoimmune myocarditis by targeting the NLRP3 inflammasome.

Authors:  Liangqi Chen; Xinyu Hou; Maomao Zhang; Yang Zheng; Xianghui Zheng; Qingyuan Yang; Jing Li; Nan Gu; Min Zhang; Yong Sun; Jian Wu; Bo Yu
Journal:  Mol Immunol       Date:  2019-11-16       Impact factor: 4.407

3.  An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.

Authors:  Françoise Solly; Catherine Koering; Aminetou Mint Mohamed; Delphine Maucort-Boulch; Guillaume Robert; Patrick Auberger; Pascale Flandrin-Gresta; Lionel Adès; Pierre Fenaux; Olivier Kosmider; Emmanuelle Tavernier-Tardy; Jérôme Cornillon; Denis Guyotat; Lydia Campos; Franck Mortreux; Eric Wattel
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

4.  A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).

Authors:  Ravi Vij; Jennifer Le-Rademacher; Kristina Laumann; Vera Hars; Kouros Owzar; Tsiporah Shore; Sumithira Vasu; Amanda Cashen; Luis Isola; Thomas Shea; Margarida DeMagalhaes-Silverman; David Hurd; Kenneth Meehan; Frank Beardell; Steven Devine
Journal:  Biol Blood Marrow Transplant       Date:  2019-06-15       Impact factor: 5.742

5.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

6.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

7.  A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Authors:  Amer M Zeidan; Hanna A Knaus; Tara M Robinson; Andrea M H Towlerton; Edus H Warren; Joshua F Zeidner; Amanda L Blackford; Amy S Duffield; David Rizzieri; Mark G Frattini; Yair M Levy; Mark A Schroeder; Anna Ferguson; Katherine E Sheldon; Amy E DeZern; Ivana Gojo; Steven D Gore; Howard Streicher; Leo Luznik; B Douglas Smith
Journal:  Clin Cancer Res       Date:  2018-05-01       Impact factor: 12.531

8.  A framework for variation discovery and genotyping using next-generation DNA sequencing data.

Authors:  Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly
Journal:  Nat Genet       Date:  2011-04-10       Impact factor: 38.330

9.  SIFT web server: predicting effects of amino acid substitutions on proteins.

Authors:  Ngak-Leng Sim; Prateek Kumar; Jing Hu; Steven Henikoff; Georg Schneider; Pauline C Ng
Journal:  Nucleic Acids Res       Date:  2012-06-11       Impact factor: 16.971

10.  Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.

Authors:  Digdem Yoyen-Ermis; Gurcan Tunali; Ece Tavukcuoglu; Utku Horzum; Didem Ozkazanc; Tolga Sutlu; Yahya Buyukasik; Gunes Esendagli
Journal:  Sci Rep       Date:  2019-08-12       Impact factor: 4.379

View more
  2 in total

1.  Lymphocyte Activation Gene 3 Single-Nucleotide Polymorphisms in Bone Marrow Failure Diseases.

Authors:  Yingying Sun; Qiuying Cao; Xiaoyu Zhao; Chunyan Liu; Zonghong Shao
Journal:  Anal Cell Pathol (Amst)       Date:  2022-02-27       Impact factor: 2.916

2.  Evaluating the Effect of 3'-UTR Variants in DICER1 and DROSHA on Their Tissue-Specific Expression by miRNA Target Prediction.

Authors:  Dmitrii S Bug; Artem V Tishkov; Ivan S Moiseev; Natalia V Petukhova
Journal:  Curr Issues Mol Biol       Date:  2021-07-06       Impact factor: 2.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.